439 related articles for article (PubMed ID: 22807680)
1. Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n.
Refsland EW; Hultquist JF; Harris RS
PLoS Pathog; 2012; 8(7):e1002800. PubMed ID: 22807680
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
[TBL] [Abstract][Full Text] [Related]
3. Catalytic activity of APOBEC3F is required for efficient restriction of Vif-deficient human immunodeficiency virus.
Albin JS; Brown WL; Harris RS
Virology; 2014 Feb; 450-451():49-54. PubMed ID: 24503066
[TBL] [Abstract][Full Text] [Related]
4. Possible footprints of APOBEC3F and/or other APOBEC3 deaminases, but not APOBEC3G, on HIV-1 from patients with acute/early and chronic infections.
Armitage AE; Deforche K; Welch JJ; Van Laethem K; Camacho R; Rambaut A; Iversen AK
J Virol; 2014 Nov; 88(21):12882-94. PubMed ID: 25165112
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 restriction by endogenous APOBEC3G in the myeloid cell line THP-1.
Ikeda T; Molan AM; Jarvis MC; Carpenter MA; Salamango DJ; Brown WL; Harris RS
J Gen Virol; 2019 Jul; 100(7):1140-1152. PubMed ID: 31145054
[TBL] [Abstract][Full Text] [Related]
6. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo.
Liddament MT; Brown WL; Schumacher AJ; Harris RS
Curr Biol; 2004 Aug; 14(15):1385-91. PubMed ID: 15296757
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms of the cytidine deaminase APOBEC3F have different HIV-1 restriction efficiencies.
Mohammadzadeh N; Follack TB; Love RP; Stewart K; Sanche S; Chelico L
Virology; 2019 Jan; 527():21-31. PubMed ID: 30448640
[TBL] [Abstract][Full Text] [Related]
8. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
[TBL] [Abstract][Full Text] [Related]
9. Different mutagenic potential of HIV-1 restriction factors APOBEC3G and APOBEC3F is determined by distinct single-stranded DNA scanning mechanisms.
Ara A; Love RP; Chelico L
PLoS Pathog; 2014 Mar; 10(3):e1004024. PubMed ID: 24651717
[TBL] [Abstract][Full Text] [Related]
10. Suppression of HIV-1 infection by APOBEC3 proteins in primary human CD4(+) T cells is associated with inhibition of processive reverse transcription as well as excessive cytidine deamination.
Gillick K; Pollpeter D; Phalora P; Kim EY; Wolinsky SM; Malim MH
J Virol; 2013 Feb; 87(3):1508-17. PubMed ID: 23152537
[TBL] [Abstract][Full Text] [Related]
11. APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis.
Sadler HA; Stenglein MD; Harris RS; Mansky LM
J Virol; 2010 Jul; 84(14):7396-404. PubMed ID: 20463080
[TBL] [Abstract][Full Text] [Related]
12. Simian Immunodeficiency Virus Vif and Human APOBEC3B Interactions Resemble Those between HIV-1 Vif and Human APOBEC3G.
Wang J; Shaban NM; Land AM; Brown WL; Harris RS
J Virol; 2018 Jun; 92(12):. PubMed ID: 29618650
[TBL] [Abstract][Full Text] [Related]
13. Turning up the volume on mutational pressure: is more of a good thing always better? (A case study of HIV-1 Vif and APOBEC3).
Pillai SK; Wong JK; Barbour JD
Retrovirology; 2008 Mar; 5():26. PubMed ID: 18339206
[TBL] [Abstract][Full Text] [Related]
14. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1.
Hultquist JF; Lengyel JA; Refsland EW; LaRue RS; Lackey L; Brown WL; Harris RS
J Virol; 2011 Nov; 85(21):11220-34. PubMed ID: 21835787
[TBL] [Abstract][Full Text] [Related]
15. APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages.
Chaipan C; Smith JL; Hu WS; Pathak VK
J Virol; 2013 Jan; 87(1):444-53. PubMed ID: 23097438
[TBL] [Abstract][Full Text] [Related]
16. Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function.
Albin JS; Haché G; Hultquist JF; Brown WL; Harris RS
J Virol; 2010 Oct; 84(19):10209-19. PubMed ID: 20686027
[TBL] [Abstract][Full Text] [Related]
17. APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication.
Han Y; Wang X; Dang Y; Zheng YH
PLoS Pathog; 2008 Jul; 4(7):e1000095. PubMed ID: 18604271
[TBL] [Abstract][Full Text] [Related]
18. Identification of a critical T(Q/D/E)x5ADx2(I/L) motif from primate lentivirus Vif proteins that regulate APOBEC3G and APOBEC3F neutralizing activity.
Dang Y; Wang X; York IA; Zheng YH
J Virol; 2010 Sep; 84(17):8561-70. PubMed ID: 20592083
[TBL] [Abstract][Full Text] [Related]
19. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G.
Holmes RK; Koning FA; Bishop KN; Malim MH
J Biol Chem; 2007 Jan; 282(4):2587-95. PubMed ID: 17121840
[TBL] [Abstract][Full Text] [Related]
20. The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H.
Binka M; Ooms M; Steward M; Simon V
J Virol; 2012 Jan; 86(1):49-59. PubMed ID: 22013041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]